Abstract Introduction: Genotoxicity testing is necessary to address potential mutagenic characteristics of pharmaceutical candidates and medical devices depending on their intended use. Adapting such tests to contact lens multipurpose solutions (MPS) may be required due to their antimicrobial nature or to fulfill specific regulatory requirements. We describe a novel methodology for genotoxicity and biocompatibility evaluation of MPS in the context of traditional testing. Materials and Methods: Blink RevitaLens® Multipurpose Disinfecting Solution (MPDS) or contact lens (Acuvue® Advance and Acuvue® 2 brand) extracts were tested by Ames assay and Chromosome Aberration (ChrAb) Assays. A novel procedure for cycling contact lenses in MPDS was developed for testing. Before assays with the Blink RevitaLens MPDS disinfectant ingredient, Alexidine Dihydrochloride (ALX) was diluted for dose-range tests identifying TA100 or Chinese Hamster Ovary cytotoxicity levels to determine the amount of ALX appropriate for each ...